Structure Therapeutics Inc.

Stocks

Market Closed - Nasdaq 16:00:00 2026-09-11 EDT			5-day change	1st Jan Change
38.66 ^USD	-2.25%		-18.34%	-44.41%

09-08	Structure Therapeutics Inc. - Special Call
09-08	Structure Therapeutics Reports Up to 16.2% Weight Loss in Aleniglipron Trial	MT

Published on 09/08/2026 at 01:51 pm EDT - Modified on 09/08/2026 at 07:06 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to the Structure Therapeutics conference call. [Operator Instructions] Please be advised today's conference is being

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

09-08	Structure Therapeutics Inc. - Special Call
09-08	Structure Therapeutics Reports Up to 16.2% Weight Loss in Aleniglipron Trial	MT
09-08	Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin And GLP-1 Programs For Chronic Weight Management	CI
08-06	Structure Therapeutics Inc. Plans to Report New Data from the Following Aleniglipron Clinical Trials in the Second Half of 2026	CI
08-06	Structure Therapeutics Inc. Announces Appointment of John Berrios as Chief Commercial Officer	CI
08-06	Structure Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-07	Race to launch weight-loss pills heats up as smaller players advance	RE
07-07	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
06-11	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
06-11	Race to launch weight-loss pill heats up as Novo wins UK approval	RE
06-09	Structure Therapeutics Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 10:00 AM
06-09	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
06-05	Structure's experimental obesity pill shows no signs of liver injury	RE
06-05	Structure Therapeutics Announces Publication In Nature Medicine Highlighting Phase 2b ACCESS Program Of Aleniglipron For Obesity	CI
05-07	Structure Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI